Morpholinyl compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein G is aryl or a 5-6 membered heteroaromatic or 8-11 membered heteroaromatic group, which may be benzofused or optionally substituted by 1-4 substituents selected from halogen, cyano, hydroxyl, amino, C1-4alkylamino, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl, SF5, C(=O)NH2 and C(=O)OR4； W is S, SO2, O, CHR2, NR4； n is 0 or 1； m and p are 1 or 2； z is 1-7； R and R4 are hydrogen or C1-4alkyl； R1 is hydrogen, C1-4alkyl； C1-4alkoxy； R2 and R3 are hydrogen, F, C1-4alkyl； OH, C1-4alkoxy； G1 is a phenyl group or a 5-6-membered heteroaromatic group or a 8-11 membered heteroaromatic group, optionally substituted by 1-4 substituents selected from halogen, cyano, hydroxyl, amino, C1-4alkylamino, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl, SF5, C(=O)NH2 or C(=O)OR4, C(=O)OR4； Y is H or an optionally substituted moiety selected from 5-6 membered heteroaromatic group, saturated mono 3-7 membered carbocyclic group or 8-11 membered bicyclic carbocyclic group in which one or more atom carbons may be replaced by NR4, O, S； may be useful as modulators of dopamine D3 receptors, e.g. to treat drug dependency or psychotic disorders such as schizophrenia.
